The Fetal Bovine Serum Market to reach $X Billion by 2030; Rising demand for advanced cell culture technologies, the growth of biopharmaceutical research, increasing applications in vaccine production, stem cell therapies, and regenerative medicine,

The Fetal Bovine Serum Market size is estimated to reach $X Billion by 2030, growing at a CAGR of 6.6% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “Fetal Bovine Serum Market - By Product ( Charcoal Stripped, Chromatographic, Dialyzed Fetal Bovine Serum, Exosome Depleted Stem Cell, Other Products), By Application ( Cell Culture, Biopharmaceuticals, Vaccines Development, Gene Therapy, Regenerative Medicine, Diagnostic Research), By End User ( Research and Academic Institutes, Biopharmaceutical Companies, Contract Research Organizations (CROs), Hospitals and Diagnostic Labs)and By Geography - Opportunity Analysis & Industry Forecast, 2024-2030.

The increasing demand for biopharmaceuticals is driving the growth of the fetal bovine serum (FBS) market. Advancements in regenerative medicine will be fueling the market growth, as they require high-quality cell cultures for tissue development and therapeutic applications.

In 2023, the North America region held the largest share of 6.6% in the Fetal Bovine Serum Market, due to its advanced livestock industry, extensive infrastructure, and regulatory environment. The U.S. and Canada are home to large-scale cattle farming operations, providing a steady and reliable source of high-quality bovine blood for FBS extraction. According to the USDA's August 2024 article, the National Agricultural Statistics Service’s latest Census of Agriculture reports that more than 622,000 of the 1.9 million U.S. farms—about 33 percent—had at least one beef cow at the end of 2022. Of those farms, approximately 55 percent had fewer than 20 beef cows. U.S. beef production is projected to rise by 2 percent, reaching a record 21.7 million tons. In Canada, the USDA’s September 2024 article forecasts that beef exports will remain strong as a percentage of production, while imports are expected to decrease due to weakened consumer demand. The Canadian swine herd is also predicted to stay stable in 2025. These factors contribute to North America’s position as a dominant player in the global FBS market. The region’s biotechnology and pharmaceutical industries further drive the demand for FBS, while strict quality control standards ensure consistency and safety. With a strong regulatory framework and a well-developed distribution network, North America is recognized as a reliable and trusted source of FBS globally.

FBS is crucial for the production of biopharmaceuticals such as vaccines, therapeutic proteins, and monoclonal antibodies, as it supports cell culture media by providing essential growth factors and nutrients for mammalian cell growth. As the global demand for biopharmaceuticals continues to rise driven by an increase in chronic diseases, advancements in personalized medicine, and ongoing vaccine development, the need for high-quality FBS also grows. According to a January 2024 article by IQVIA, global medicine use grew by 14% over the past five years, with a further 12% expected increase through 2028, bringing annual use to 3.8 trillion defined daily doses. Additionally, global spending on medicine, based on list prices, grew by 35% over the last five years and is projected to increase by 38% through 2028. This surge in medicine use and spending highlights the expanding need for raw materials like FBS to support the production of essential biopharmaceutical products. 

As regenerative medicine progresses, particularly with technologies like 3D bioprinting, there is an increasing need for high-quality FBS to support the growth and development of complex tissues. For instance, in February 2024, a breakthrough was made in 3D bioprinting when researchers at the University of Wisconsin-Madison developed a novel method for printing functional human brain tissue. Similarly, researchers at the Vienna University of Technology have made strides in generating replacement tissue, specifically for treating injured cartilage, through lab-based 3D printing. These advancements in tissue engineering and regenerative therapies require precise and nutrient-rich cell cultures, where FBS plays a vital role by providing essential growth factors for the cells. As the potential applications of regenerative medicine expand, so too does the need for FBS to ensure the successful cultivation of human tissues for therapeutic purposes. This growing field is contributing significantly to the demand for FBS in both research and clinical settings.

• In November 2024, Gemini Bioproducts, LLC, a prominent supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC, announced the acquisition of specific fetal bovine serum (FBS) product rights and inventory from Bio-Techne.

• In June 2024, JTA International Investment Holding and KZA Medical forged a partnership to develop a cutting-edge pharmaceutical production complex in Turkey with an investment of more than $53 million. The first phase of investment includes the development of a factory dedicated to producing animal and human serums.

Corning Incorporated, Merck KGaA, Cytiva, Takara Bio Inc., Thermo Fisher Scientific, Bovogen Biologicals Pvt Ltd, PAN-Biotech, HiMedia Laboratories, Capricorn Scientific, Nucleus Biologics LLC and others.

Global Bovine Colostrum Market- The Global Bovine Colostrum market is estimated to be $229.4 million in 2021 growing at a CAGR of 3.8% over the forecast period 2022-2027 owing to demand for immune-boosting products, growing awareness of the health benefits of colostrum, rising consumer preference for natural supplements, and its expanding use in the pharmaceutical, functional food, and cosmetic industries.

Cell-Free Fetal DNA Testing Market- The Cell-Free Fetal DNA Testing Market size is estimated to reach $3025.1 million by 2030, growing at a CAGR of 10.90% during the forecast period 2024-2030. Increasing demand for non-invasive prenatal testing (NIPT), growing awareness of early disease detection, advancements in genetic testing technologies, and rising adoption of personalized healthcare are fueling the market growth.

3D Cell Culture Market - The 3D cell culture market size is estimated to reach $1.9 billion by 2027 and is poised to grow at a CAGR of 11.1% over the forecast period of 2022-2027, driven by advancements in medical technology, rising demand for non-invasive diagnostic solutions, growing applications in personalized medicine, and increasing investments in research and development for improved disease detection and therapeutic solutions.

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.  

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format that assists an intelligent and informed decision-making process.

Mr. Venkat Reddy

IndustryARC

Email: [email protected]

USA: (+1) 518-282-4727

Web: https://www.industryarc.com

Follow us on LinkedIn | Facebook | Twitter